Skip to main content
main-content

Pediatric rheumatology

Medications

14-06-2019 | Juvenile idiopathic arthritis | EULAR 2019 | News

Similar JIA outcomes with switch to second TNF inhibitor vs alternative biologic

Juvenile idiopathic arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapy have similar outcomes regardless of whether they switch to a second agent from the same class or an alternative biologic, research suggests.

07-05-2019 | Systemic lupus erythematosus | Article

Editorial board comment

Comment on: Belimumab approved for pediatric lupus in the USA

ACR/National Arthritis Foundation guidelines for managing JIA released

The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.

07-05-2019 | Juvenile idiopathic arthritis | Highlight | News

ACR/National Arthritis Foundation guidelines for managing JIA released

The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.

29-04-2019 | Etanercept biosimilar | News

FDA approves etanercept biosimilar

Click through for more information on this announcement

27-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

Temporomandibular joint involvement in juvenile idiopathic arthritis: Diagnosis and management

The authors provide an overview of temporomandibular joint involvement in children with juvenile idiopathic arthritis, including imaging methods for diagnosis, clinical examination recommendations, and treatment options.

Temporomandibular joint involvement in juvenile idiopathic arthritis: Diagnosis and management

The authors provide an overview of temporomandibular joint involvement in children with juvenile idiopathic arthritis, including imaging methods for diagnosis, clinical examination recommendations, and treatment options.

28-02-2019 | Juvenile idiopathic arthritis | News

Substantial proportion of patients with JIA have ongoing disease as adults

Almost half of patients with juvenile idiopathic arthritis have ongoing active disease during early adulthood, with the burden particularly high among those with enthesitis-related arthritis, researchers report.

22-02-2019 | Adalimumab biosimilar | News

EMA gives nod to two adalimumab biosimilars

The Committee for Medicinal Products for Human Use has recommended two new adalimumab biosimilars for approval in Europe.

14-12-2018 | Pediatric | Article

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Jung JY et al. Pediatr Rheumatol 2018; 16: 79. doi: 10.1186/s12969-018-0296-z

26-11-2018 | Juvenile idiopathic arthritis | News

Disease subtype, treatment choice may impact infection risk in JIA patients

Among biologic-treated patients with juvenile idiopathic arthritis, infection risk may differ according to disease subtype and the biologic agent used, researchers report.

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

18-10-2018 | Infection | Editorial | Article

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

15-10-2018 | Juvenile idiopathic arthritis | News

Response to canakinumab sustained for up to 5 years in children with sJIA

Response to canakinumab therapy is sustained or even improved for up to 5 years in children with systemic juvenile idiopathic arthritis, with no new safety signals, according to the results of a long-term extension study published in the Annals of the Rheumatic Diseases.

01-10-2018 | Juvenile idiopathic arthritis | Review | Article

Glucocorticoid treatment in juvenile idiopathic arthritis

Batu ED. Rheumatol Int 2018. doi: 10.1007/s00296-018-4168-0

Increased risk for preterm delivery in women with RA and JIA

Women with rheumatoid arthritis and those with juvenile idiopathic arthritis have a significantly elevated risk for preterm delivery, according to a prospective cohort study published in Arthritis Care & Research.

06-09-2018 | Pregnancy | Highlight | News

Increased risk for preterm delivery in women with RA and JIA

Women with rheumatoid arthritis and those with juvenile idiopathic arthritis have a significantly elevated risk for preterm delivery, according to a prospective cohort study published in Arthritis Care & Research.

21-08-2018 | Juvenile idiopathic arthritis | Article

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra

Kearsley-Fleet L et al. Rheumatology (Oxford) 2018: key262. doi: 10.1093/rheumatology/key262

Image Credits